IL6 and metabolic syndrome: Similar results were reported by Rehman et al. (2017) and Lehrskov et al. (2019), who demonstrated that IL-6 affected specific components of metabolic syndrome, such as dyslipidemia and insulin resistance, but was not a primary determinant of the development of MetS as a whole [61,62].